Adaptation of HIV-1 depends on the host-cell environment

PLoS ONE

Volumn 2, Issue 3, 2007, Pages

  van Opijnen, Tim ^a,b   de Ronde, Anthony ^a   Boerlijst, Maarten C ^b   Berkhout, Ben ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CYAN FLUORESCENT PROTEIN; LYSINE; TYROSINE; VIRUS ENVELOPE PROTEIN; YELLOW FLUORESCENT PROTEIN;

AMINO ACID SUBSTITUTION; ARTICLE; CELL EXPANSION; CELL LINE; CELL STRAIN C8166; CELL STRAIN MT4; CELL TYPE; EVOLUTIONARY ADAPTATION; GENE MUTATION; GENETIC POLYMORPHISM; HUMAN IMMUNODEFICIENCY VIRUS 1; LONG TERMINAL REPEAT; NONHUMAN; SEQUENCE ANALYSIS; STRAIN DIFFERENCE; T LYMPHOCYTE; VIRUS CELL INTERACTION; VIRUS CULTURE; VIRUS GENOME; VIRUS RECOMBINATION; VIRUS STRAIN; ACCLIMATIZATION; ACQUIRED IMMUNE DEFICIENCY SYNDROME; DISEASE COURSE; EVOLUTION; GENETIC VARIABILITY; GENETICS; GENOTYPE; HOST PARASITE INTERACTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PATHOPHYSIOLOGY; PHYSIOLOGY; TIME; VIROLOGY; VIRUS REPLICATION;

HUMAN IMMUNODEFICIENCY VIRUS 1;

ACCLIMATIZATION; ACQUIRED IMMUNODEFICIENCY SYNDROME; CELL LINE; DISEASE PROGRESSION; EVOLUTION; GENETIC VARIATION; GENOTYPE; HIV INFECTIONS; HIV LONG TERMINAL REPEAT; HIV-1; HOST-PARASITE INTERACTIONS; HUMANS; POLYMORPHISM, GENETIC; T-LYMPHOCYTES; TIME FACTORS; VIRUS REPLICATION;

EID: 55849104323     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0000271     Document Type: Article

References (84)

1. Valdez H, Carlson NL, Post AB, Asaad R, Heeger PS, et al. (2002) HIV long-term non-progressors maintain brisk CD8 T cell responses to other viral antigens. AIDS 16: 1113-1118.
2. Guadalupe M, Reay E, Sankaran S, Prindiville T, Flamm J, et al. (2003) Severe CD4+T-cell depletion in gut lymphoid tissue during primary human immunodeficiency virus type 1 infection and substantial delay in restoration following highly active antiretroviral therapy. J Virol 77: 11708-11717.
3. Korthals AH, de Boer R, Boerlijst M (2006) Role of avidity and breadth of the CD4 T cell response in progression to AIDS. Proc Biol Sci 273: 1697-1704.
4. Van Opijnen T, Berkhout B (2005) The host environment drives HIV-1 fitness. RevMed Virol 15: 219-233.
5. Perelson AS, Neumann AU, Markowitz M, Leonard JM, Ho DD (1996) HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science 271: 1582-1586.
6. Rodrigo AG, Shpaer EG, Delwart EL, Iversen AK, Gallo MV, et al. (1999) Coalescent estimates of HIV-1 generation time in vivo. Proc Natl Acad Sci U S A 96: 2187-2191.
7. Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, et al. (1995) Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 373: 123-126.
8. Wei X, Ghosh SK, Taylor ME, Johnson VA, Emini EA, et al. (1995) Viral dynamics in human immunodeficiency virus type 1 infection. Nature 373: 117-126.
9. Mansky LM, Temin HM (1995) Lower in vivo mutation rate of human immunodeficiency virus type 1 than predicted from the fidelity of purified reverse transcriptase. The Journal of Virology 69: 5087-5094.
10. Kellam P, Larder BA (1995) Retroviral recombination can lead to linkage of reverse transcriptase mutations that confer increased zidovudine resistance. J Virol 69: 669-674.
11. Moutouh L, Corbeil J, Richman DD (1996) Recombination leads to the rapid emergence of HIV-1 dually resistant mutants under selective drug pressure. Proc Natl Acad Sci U S A 93: 6106-6111.
12. Van Opijnen T, Jeeninga RE, Boerlijst MC, Pollakis GP, Zetterberg V, et al. (2004) Human immunodeficiency virus type 1 subtypes have a distinct long terminal repeat that determines the replication rate in a host-cell-specific manner. J Virol 78: 3675-3683.
13. Hemonnot B, Cartier C, Gay B, Rebuffat S, Bardy M, et al. (2004) The host cell MAP kinase ERK-2 regulates viral assembly and release by phosphorylating the p6gag protein of HIV-1. J Biol Chem 279: 32426-32434.
14. Levy DN, Aldrovandi GM, Kutsch O, Shaw GM (2004) Dynamics of HIV-1 recombination in its natural target cells. Proc Natl Acad Sci U S A 101: 4204-4209.
15. Negroni M, Buc H (2001) Mechanisms of retroviral recombination. AnnuRevGenet 35: 275-302.
16. Boerlijst MC, Bonhoeffer S, Nowak MA (1996) Viral quasi-species and recombination. Proc R SocLond B Biol Sci 263: 1577-1584.
17. Leitner T, Escanilla D, Marquina S, Wahlberg J, Brostrom C, et al. (1995) Biological and molecular characterization of subtype D, G, and A/ D recombinant HIV-1 transmissions in Sweden. Virology 209: 136-146.
18. Charpentier C, Nora T, Tenaillon O, Clavel F, Hance AJ (2006) Extensive recombination among human immunodeficiency virus type 1 quasispecies makes an important contribution to viral diversity in individual patients. J Virol 80: 2472-2482.
19. Sabino E, Pan LZ, Cheng-Mayer C, Mayer A (1994) Comparison of in vivo plasma and peripheral blood mononuclear cell HIV-1 quasispecies to short-term tissue culture isolates: an analysis of tat and C2-V3 env regions. AIDS 8: 901-909.
20. Rouzine IM, Coffin JM (2005) Evolution of human immunodeficiency virus under selection and weak recombination. Genetics 170: 7-18.
21. Bocharov G, Ford NJ, Edwards J, Breinig T, Wain-Hobson S, et al. (2005) A genetic-algorithm approach to simulating human immunodeficiency virus evolution reveals the strong impact of multiply infected cells and recombination. J Gen Virol 86: 3109-3118.
22. Althaus CL, Bonhoeffer S (2005) Stochastic interplay between mutation and recombination during the acquisition of drug resistance mutations in human immunodeficiency virus type 1. J Virol 79: 13572-13578.
23. Fisher RA (1930) The Genetical Theory of Natural Selection. Oxford, UK: Oxford University Press.
24. Muller HJ (1932) Some genetic aspects of sex. American Naturalist 66: 118-138.
25. Otto SP, Lenormand T (2002) Resolving the paradox of sex and recombination. NatRev Genet 3: 252-261.
26. Maynard Smith J (1978) The Evolution of Sex. Cambridge, UK: Cambridge University Press.
27. Rice WR (2002) Experimental tests of the adaptive significance of sexual recombination. NatRev Genet 3: 241-251.
28. Maynard Smith J (1968) Evolutionin sexual and asexual populations. American Naturalist 102: 469-473.
29. Eshel I, Feldman MW (1970) On the evolutionary effect of recombination. TheorPopulBiol 1: 88-100.
30. Peden K, Emerman M, Montagnier L (1991) Changes in growth properties on passage in tissue culture of viruses derived from infectious molecular clones of HIV-1 LAI , HIV-1 MAL , and HIV-1 ELI Virology 185: 661-672.
31. Ross EK, Buckler White AJ, Rabson AB, Englund G, Martin MA (1991) Contribution of NF-kappa B and Sp1 binding motifs to the replicative capacity of human immunodeficiency virus type 1: distinct patterns of viral growth are determined by T-cell types. The Journal of Virology 65: 4350-4358.
32. Smith SD, Shatsky M, Cohen PS, Warnke R, Link MP, et al. (1984) Monoclonal antibody and enzymatic profiles of human malignant T-lymphoid cells and derived cell lines. Cancer Res 44: 5657-5660.
33. Van Opijnen T, Boerlijst MC, Berkhout (2006) Effects of random mutations in the Human Immunodeficiency Virus type I transcriptional promoter on viral fitness in different host-cell environments. J Virol, in press.
34. Ebert D (1998) Experimental evolution of parasites. Science 282: 1432-1435.
35. Eigen M (1987) New concepts for dealing with the evolution of nucleic acids. Cold Spring HarbSympQuantBiol 52: 307-320.
36. Kauffman SA (1993) The Origins of Order. Oxford Univ. Press, New York.
37. Fu YX, Li WH (1993) Statistical tests of neutrality of mutations. Genetics 133: 693-709.
38. Miralles R, Gerrish PJ, Moya A, Elena SF (1999) Clonal interference and the evolution of RNA viruses. Science 285: 1745-1747.
39. Miralles R, Moya A, Elena SF (2000) Diminishing returns of population size in the rate of RNA virus adaptation. J Virol 74: 3566-3571.
40. Hill WG, Robertson A (1966) The effect of linkage on limits to artificial selection. GenetRes 8: 269-294.
41. Barton NH (1995) Linkage and the limits to natural selection. Genetics 140: 821-841.
42. Gerrish PJ, Lenski RE (1998) The fate of competing beneficial mutations in an asexual population. Genetica 102-103: 127-144.
43. Orr HA (2000) The rate of adaptation in asexuals. Genetics 155: 961-968.
44. Kim Y, Stephan W (2003) Selective sweeps in the presence of interference among partially linked loci. Genetics 164: 389-398.
45. de Visser JA, Zeyl CW, Gerrish PJ, Blanchard JL, Lenski RE (1999) Diminishing returns from mutation supply rate in asexual populations. Science 283: 404-406.
46. Otto SP, Barton NH (1997) The evolution of recombination: removing the limits to natural selection. Genetics 147: 879-906.
47. Hey J (1998) Selfish genes, pleiotropy and the origin of recombination. Genetics 149: 2089-2097.
48. Butcher D (1995) Muller's ratchet, epistasis and mutation effects. Genetics 141: 431-437.
49. Gordo I, Charlesworth B (2000) On the speed of Muller's ratchet. Genetics 156: 2137-2140.
50. Gessler DD (1995) The constraints of finite size in asexual populations and the rate of the ratchet. GenetRes 66: 241-253.
51. Novella IS, Elena SF, Moya A, Domingo E, Holland JJ (1995) Size of genetic bottlenecks leading to virus fitness loss is determined by mean initial population fitness. J Virol 69: 2869-2872.
52. Wright S (1932) The roles of mutation, inbreeding, crossbreeding and selection in evolution. Proc Sixth Int Congress Genetics 1: 356-366.
53. Back NKT, Nijhuis M, Keulen W, Boucher CAB, Oude Essink BB, et al. (1996) Reduced replication of 3TC-resistant HIV-1 variants in primary cells due to a processivity defect of the reverse transcriptase enzyme. The EMBO Journal 15: 4040-4049.
54. Boucher CAB, O'Sullivan E, Mulder JW, Ramautarsing C, Kellam P, et al. (1992) Ordered appearance of zidovudine resistance mutations during treatment of 18 human immunodeficiency virus-positive subjects. Journal of Infectious Diseases 165: 105-110.
55. Larder BA (1994) Interactions between drug resistance mutations in human immunodeficiency virus type 1 reverse transcriptase. Journal of General Virology 75: 951-957.
56. Keulen W, Boucher C, Berkhout B (1996) Nucleotide substitution patterns can predict the requirements for drug-resistance of HIV-1 proteins. Antiviral Research 31: 45-57.
57. Croteau G, Doyon L, Thibeault D, McKercher G, Pilote L, et al. (1997) Impaired fitness of human immunodeficiency virus type 1 variants with high-level resistance to protease inhibitors. The Journal of Virology 71: 1089-1096.
58. Doyon L, Payant C, Brakier-Gingras L, Lamarre D (1998) Novel Gag-Pol frameshift site in Human Immunodeficiency Virus type 1 variants resistant to Protease inhibitors. The Journal of Virology 72: 6146-6150.
59. Mammano F, Petit C, Clavel F (1998) Resistance-associated loss of viral fitness in human immunodeficiency virus type 1: phenotypic analysis of Protease and gag coevolution in protease inhibitor-treated patients. The Journal of Virology 72: 7632-7637.
60. Bleiber G, Munoz M, Ciuffi A, Meylan P, Telenti A (2001) Individual contributions of mutant protease and reverse transcriptase to viral infectivity, replication, and protein maturation of antiretroviral drug-resistant Human Immunodeficiency Virus type 1. The Journal of Virology 75: 3291-3300.
61. Berkhout B (1999) HIV-1 evolution under pressure of protease inhibitors, climbing the stairs of viral fitness. Journal Biomedical Science 6: 298-305.
62. Deeks SG, Wrin T, Liegler T, Hoh R, Hayden M, et al. (2001) Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia. The New England Journal of Medicine 344: 472-480.
63. Frenkel LM, Mullins JI (2001) Should patients with drug-resistant HIV-1 continue to receive antiretroviral therapy? The New England Journal of Medicine 344: 520-522.
64. Zaccarelli M, Tozzi V, Perno CF, Antinori A (2004) The challenge of antiretroviral-drug-resistant HIV: is there any possible clinical advantage? CurrHIV Res 2: 283-292.
65. Clementi M (2004) Can modulation of viral fitness represent a target for anti-HIV-1 strategies? New Microbiol 27: 207-214.
66. Tisdale M, Kemp SD, Parry NR, Larder BA (1993) Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3′-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase. Proc Natl Acad Sci U S A 90: 5653-5656.
67. Nijhuis M, Schuurman R, de Jong D, Erickson J, Gustchina E, et al. (1999) Increased fitness of drug resistant HIV-1 protease as a result of acquisition of compensatory mutations during suboptimal therapy. AIDS 13: 2349-2359.
68. Kondrashov AS (1984) Deleterious mutations as an evolutionary factor. 1. The advantage of recombination. GenetRes 44: 199-217.
69. Rice WR (1998) Requisite mutational load, pathway epistasis and deterministic mutation accumulation in sexual versus asexual populations. Genetica 102-103: 71-81.
70. Charlesworth B (1994) The effect of background selection against deleterious mutations on weakly selected, linked variants. GenetRes 63: 213-227.
71. Charlesworth D, Charlesworth B, Morgan MT (1995) The pattern of neutral molecular variation under the background selection model. Genetics 141: 1619-1632.
72. Peck JR (1994) A ruby in the rubbish: beneficial mutations, deleterious mutations and the evolution of sex. Genetics 137: 597-606.
73. Gu Z, Gao Q, Faust EA, Wainberg MA (1995) Possible involvement of cell fusion and viral recombination in generation of human immunodeficiency virus variants that display dual resistance to AZT and 3TC. J Gen Virol 76 ( Pt 10): 2601-2605.
74. Serviene E, Shapka N, Cheng CP, Panavas T, Phuangrat B, et al. (2005) Genome-wide screen identifies host genes affecting viral RNA recombination. Proc Natl Acad Sci USA.
75. Jeeninga RE, Hoogenkamp M, Armand-Ugon M, de Baar M, Verhoef K, et al. (2000) Functional differences between the LTR transcriptional promoters of HIV-1 subtypes A through G. The Journal of Virology 74: 3740-3751.
76. Chen BK, Feinberg MB, Baltimore D (1997) The k B sites in the Human Immunodeficiency Virus type 1 Long Terminal Repeat enhance virus replication yet are not absolutely required for viral growth. The Journal of Virology 71: 5495-5504.
77. Beck Z, Bacsi A, Liu X, Ebbesen P, Andirko I, et al. (2003) Differential patterns of human cytomegalovirus gene expression in various T-cell lines carrying human T-cell leukemia-lymphoma virus type I: role of Tax-activated cellular transcription factors. J Med Virol 71: 94-104.
78. Mohapatra S, Chu B, Wei S, Djeu J, Epling-Burnette PK, et al. (2003) Roscovitine inhibits STAT5 activity and induces apoptosis in the human leukemia virus type 1-transformed cell line MT-2. Cancer Res 63: 8523-8530.
79. Matsuo Y, Drexler HG, Harashima A, Okochi A, Shimizu N, et al. (2004) Transcription factor expression in cell lines derived from natural killer-cell and natural killer-like T-cell leukemia-lymphoma. Hum Cell 17: 85-92.
80. Larder BA, Kohli A, Kellam P, Kemp SD, Kronick M, et al. (1993) Quantitative detection of HIV-1 drug resistance mutations by automated DNA sequencing. Nature 365: 671-673.
81. Kumar S, Tamura K, Nei M (1994) Molecular evolutionary genetics analysis (MEGA). ComputApplBiosc 10: 189-191.
82. Rozas J Fau-Sanchez-DelBarrio JC, Sanchez-DelBarrio Jc Fau-Messeguer X, Messeguer X Fau-Rozas R, Rozas R Dna SP () DNA polymorphism analyses by the coalescent and other methods..
83. Lenski RE, Rose MRS, S.C.Tadler SC (1991) Long-Term experimental evolution in Escherichia coli. I. Adaptation and divergence during 2,000 generations. The American Naturalist 138: 1315-1341.
84. Maree AF, Keulen W, Boucher CA, de Boer RJ (2000) Estimating relative fitness in viral competition experiments. J Virol 74: 11067-11072.